TrovaGene Company Profile (NASDAQ:TROV)

TrovaGene trades on the NASDAQ under the ticker symbol "TROV."

TrovaGene, Inc. (NASDAQ:TROV) issued its quarterly earnings results on Tuesday, May, 10th. The company reported ($0.36) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.29) by $0.07. The firm earned $0.12 million during the quarter, compared to the consensus estimate of $0.34 million. TrovaGene had a negative net margin of 10,938.20% and a negative return on equity of 162.31%. View TrovaGene's Earnings History.

TrovaGene is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for TrovaGene.

3 brokerages have issued 1 year price objectives for TrovaGene's stock. Their predictions range from $1.80 to $8.00. On average, they expect TrovaGene's share price to reach $4.45 in the next year. View Analyst Ratings for TrovaGene.

Here are some recent quotes from research analysts about TrovaGene stock:

• 1. Maxim Group analysts commented, "The in-licensing of PCM-075 (Polo-like Kinase 1 Inhibitor, PLK1) from Nerviano Medical Sciences marked a new chapter for Trovagene as a company in precision cancer therapeutics, targeting acute myeloid leukemia (AML). We spent an evening with Trovagene Management to discuss the program in AML, the clinical path forward and how the company will leverage its knowledge- base in precision cancer monitoring (PCM) to develop PCM-075. There are multiple factors that we see as de-risking and in our view position Tovagene for success in AML. 1. The clinical path forward for a PLK inhibitor in AML has been paved by Boehringer Ingelheim’s (BI) Volasertib. A P1/2 (N=50) dose-ranging and efficacy study is expected to initiate in 2017 (data in 2018). Pending positive data, a P2/3 registration study (N=600) would likely follow. 2. Safety: Volasertib as a pan-PLK inhibitor with IV-only administration and a long half-life induced patient deaths (infections). PCM-075 only targets PLK1 (critical for cancer cell survival), has a 5X shorter half life and is oral. As such PCM-075 may be a safer, more efficacious option. 3. Precision Cancer Monitoring, PCM: Trovagene has the advantage of leveraging its existing AML cancer mutation (NPMI) test that can determine the therapeutic response to PCM-075. The company will also use the PCM platform to develop an AML multi-gene panel. Conclusion. Trovagene is now a therapeutics company and has a distinct advantage in being able to leverage its precision cancer monitoring platform to track therapeutic responses to its drug, PCM-075." (5/5/2017)
• 2. According to Zacks Investment Research, "Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. " (3/15/2017)
• 3. Cantor Fitzgerald analysts commented, "The partnership with Boreal Genomics is an important milestone for the company, in our view. Per the long-term supply and distribution agreement, 1) TROV commits upfront and milestone payments totaling $1M, 2) TROV has global distribution rights in blood and exclusively in urine for least ten years, and 3) TROV and Boreal will form a joint effort to bring the assay kits and systems through the necessary regulatory pathways for approval. Importantly, TROV continues to target the analytical validation of its initial panel by the end of 2016 and plans to launch a series of cancer-specific multigene ctDNA urine and blood panels, in partnership with Boreal, in 2017. For more details on TROV’s commercialization strategy, please see our September 30, 2016 note. The OnTarget platform separates target mutations from the wild-type. In a one-hour process, the sample is injected into a gel matrix containing short oligo probes that are complementary to the target mutations. The temperature is increased to the melting temperature of the target-probe duplex and target mutations are separated by repeated hybridization in an alternating electric field. Target alleles are collected in the extraction chamber, while the wild-type is removed with more than 1M fold enrichment (and as high as 10M fold)." (11/30/2016)

Some companies that are related to TrovaGene include Imprimis Pharmaceuticals (IMMY), Endocyte (ECYT), Xenon Pharmaceuticals (XENE), Aeglea BioTherapeutics (AGLE), IntelGenx Technologies Corp. (IGXT), ContraFect Corporation (CFRX), Fibrocell Science (FCSC), Akari Therapeutics PLC (AKTX), XOMA Corporation (XOMA), pSivida Corp. (PSDV), Sunesis Pharmaceuticals (SNSS), Juniper Pharmaceuticals (JNP), Bellerophon Therapeutics (BLPH), KemPharm (KMPH), The Joint Corp. (JYNT), Zosano Pharma Corporation (ZSAN), Aevi Genomic Medicine (GNMX) and SCYNEXIS (SCYX).

TrovaGene's management team includes the folowing people:

• Thomas H. Adams Jr. Ph.D., Chairman of the Board
• William J. Welch, Chief Executive Officer, Director
• Paul R. Billings M.D., Ph.D., Independent Director
• John P. Brancaccio CPA, Independent Director
• Gary S. Jacob Ph.D., Independent Director
• Rodney S. Markin M.D., Ph.D., Independent Director
• Stanley N. Tennant, Independent Director

TrovaGene's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include SABBY MANAGEMENT, LLC (5.70%) and Prospera Financial Services Inc (0.43%). Company insiders that own TrovaGene stock include Antonius Schuh, Mark Erlander, Stanley Tennant, Steve Zaniboni and William J Welch. View Institutional Ownership Trends for TrovaGene.

TrovaGene's stock was sold by a variety of institutional investors in the last quarter, including Prospera Financial Services Inc. View Insider Buying and Selling for TrovaGene.

Shares of TrovaGene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TrovaGene stock can currently be purchased for approximately $0.96.